Organization

Tulane University School of Medicine

3 clinical trials

2 abstracts

Abstract
Efficacy and toxicity of [177Lu]Lu-PSMA-617 for metastatic castration-resistant prostate cancer in a real-world setting: Results from the U.S. Expanded Access Program and comparisons with phase 3 VISION data.
Org: Division of Nuclear Medicine and Molecular Imaging, The Russell H. Morgan Department of Radiology and Radiological Science, Tulane University School of Medicine,
Abstract
Race and ethnicity reporting by US federal standards in high-impact phase 2/3 oncology clinical trial publications.
Org: Stanford Cancer Institute, Harvard Medical School, University of California San Francisco School of Medicine, Harvard University, Tulane University School of Medicine,